VB-85247
/ Venenum BioDesign
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 21, 2025
STING Agonist VB-85247 Induces Durable Antitumor Immune Responses by Intravesical Administration in a Non–Muscle-Invasive Bladder Cancer
(Cancer Res)
- "VB-85247 induced complete response in an orthotopic NMIBC model in contrast to treatment with BCG, which was not efficacious in the model....Activation of the STING pathway via VB-85247 induced upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, along with maturation and activation of dendritic cells. In addition, VB-85247 provided a therapeutic benefit in combination with immune checkpoint blockade using anti-PD-1 antibody treatment."
Preclinical • Bladder Cancer
1 to 1
Of
1
Go to page
1